height (Ht) SDS a t LT: -2.02 (SD 1.25). Post-LT medication: cyclosporine in tapering doses: prednisone, by daily regimen (DP) for the first 6-12 months, with tapering doses depending on clinical course, then on ;~ltcr~iatc day reglrnen (ADP). Cross-sectional st11t1.i (CSS): 9 5 children ( 5 5 M. 4 0 F) aged 0 . 1 7 to 14.88 (2 3.83). observed before LT, after LT on Dl'. a n d on ADP (same medication). Res~tits: I S : pre-LT height velocity ( I M S D S (RtSD -0 . 6 0~1 . 3 1 1 signilicaltly lowcr (])<0.01) than AD1'-HVSDS (2.841-1.59) b u t not significantly different from DP-tIVSDS 1-1.37t1.66). =: DP-HtSDS (ZlSD -1.91;t1.32) significantly lowcr (p<0.01) Ih;~n prc-LA-IILSDS (-1.071-1.06) nritl AL)I'-lltSDS 1-0.98i1.23). Similar rcsults for sitting height (Sf-l) SDS and s~11)ischial leg length (SLI.) SDS: prc-IIr a n d ADP-SLSDS significantly greater than pre-LT and ADP-Sf-ISDS (p=O.Ol): Dl'-SLLSDS not signiiicantlv different from DP-SHSDS. Slgnilicant irnprovcmcnt ofuhcatl circurnl)hercncc SDS ant1 skinfoltl ~D S on ADP. Cor~clusinns: growth in childrcn with liver discasc does not improve after LT on DP while shows catch-1111 growth on ADP; therefore, it mainly tlcpends on clinical course and corticostcroltl rcginlcn. . . -test and an 1Q evaluation before ~~iedical i~lvcstigatio~~. l'lie I<cy figure was scored anonymously according to the bou~ldary type errors defined as non developmental severe distorlio~~s or d~stc.\pucl uf bou~ldarics. 23 cl~ildrc~i Ii;~d nu~ri~itl ilod I7 llitd abnormal GII-secretion. Among 1liose,4 clrildrc~l had colliplete and 13 had partial GI1 dcficie~~cy but ;ill of tllc~ri ilad low nocturnal GI[-sccrctioi~ (AUCb < 85 ndmV1211). I7 cllildrc~i Ilnd a I I O~I I I ;~~ Rey figure illid 23 h:ld boundary type errors. Mean IQ was nornlal ill boll1 groups. ' The bioloyic;ll 2nd tile psyclrological a~lalysis were ill agrcclllcnt ill 32 ciiildrc~i (p < 0.0005). Night GII-sccretio~~ was lower (p < 0.006) in cllildre~i will1 bou~iclary typc errols (AUCb lnlean i SEA1 88.5 ?r 8 nd111Vl211) as co~nparcd to cliildre~i will1 ~ior~ilsl Rev figure (AUCb 140.7 ?-17.9). To Investigate the GH-induced changes in body composltlon we studled the lean and fat tissues, bone mineral content (BMC) and density (BMD) of GH-deficient children by DEXA (Lunar, WI), before and after they were 174214 days on hGH (0.075 U/Kg/day). E~ght pre-pubertal children (4 boys), aging 6.2-14.1 yr (bone ages: 2-9 yr), were enrolled. All had peak GH responses to clonidlne and insulln < 5 ng/ml. BEFORE GH was given, body fat (4.222.5 kg) was distributed a s 31+15 % in arms, 2 5~1 0 % In legs and 2 0~1 0 % in abdomen (abdrn), while body lean tissue (13.723.1 kg) was 4 7 2 3 % in abdm, 24+2 % in legs and 1 0~4 % in arms. Total BMC was 0.64+0.16 kg, of which 4 7~7 %was in the head, 2524 % In legs and 9 2 1 % in arms. Total BMD (g/cm2) was 0.8i0.04; it was higher In the head (1.4+0.1), followed by legs (0.6+0.074), pelvis ( 0 . 6~0 . 0 5 ) , spine (0.6+0.01) and arms (0.5+0.03). GH treatment resulted in (i) height increase (4.621 cm; p>0.05) and no change in body weight (t0.921.4 Kg; p>0.05); (11) decreased body fat (-32216 %; p<0.05: -4 2~3 2 % in arms, -30210 in abdrn and -29i20 % in legs); (i~i) increased lean body mass (1 11+12 %; ~~0 . 0 5 : +26+9 % ~n legs); (iv) increased BMC ( 7 2 6 %; p<0.05: -5 2 4 % in the head; t21+21 % in arms; t 1 8 i 9 % in legs): (v) decreased BMD (-2.3+2.9 %; ~~0 . 0 5 : -6.424.3 % In the head, t 6 . 9~6 . 6 % in pelvis, +4.3*3.1 % ~n arms, +3.7+2.2 % in legs). In conclusion, GH treatment caused body fat to decrease and lean mass to increase; because BMC increased significantly, the lower BMD is probably related to increased bone surface. GllP is n ~~o l c l~t ;111d spccilic sti~liul;ltor ol gr~iwth iior~~lone (GH) secrctlon. I t IS a 6 aminoacid peptide with lower ~i~olectil:~r wcight a11d iongur l1;llr lifc tl1:111 GRF, To cl.irii'y IIOW tlii) 1)cl)iidc ircts, we irdl~r~~l~~iured separately and togctiler I i~glkg bolus doses ol GRI' and GRF iv to 22 cl~ildren (13 M, 9 F), ages 3-16 years, with previously doci~rncntcd GHD. Tests were separated by at least I week. Bone ages rnngetl fro111 1-10 years arid growth vulocities were less iliati 3 c1111year. GH was ~neasured by RIA with an intranssny cv of5 %. A ~) o s~t~v c response was defined as a Gfl increase grcntcr tila11 4 cv's. We observed I? ( 5 6 % ) posltlve responses lo GI<I', and IS pos~tivc responses to GIIF (68 %). Nineteen (86 %) patients responded to both peptitles ad~ninistcred together. Out of tire 12 GRP responders only 9 pnlicnts had a pos~tive response to GRF, and out of tile 15 GRF rcspo~idcrs ollly 9 li.!ti n [)osilivc rcsl)onsc lu Gill'. GH pall; lcvcls were observed between 5 and 60 illin (11len11 30 min) alter Gill:, and bctwecn 10-45 min (~nean 24 III~II) aficr GIl1'. We conclude that GIII' i\ ;I ~potc~~t sccrct;igoguc of growth lior~ilonc i n a subatanti;ll proportlor of GI1 delicicr~t ch~ldre~i. Tllc dissociaicd response to GRI' and GIIF suggests that ti~cy stilill~lntc GI1 release througli cliircrc~~t I I I~~~I ; I I I~\ I I I \ , Recent data irdicate t h e senm' concentration of IGFW-3 (the m j o r p t -n a t a l IGF b i r d i q protein) m y be c l i n i c a l l y iqmrtant in scme pathophysiolqic states. D t i s t i q rross-sectiml data s-est an ontcgeny e x i s t s for IGF'BP3, with levels -ing with age and pealiin3 during plberty. To investigate the pattern of change in IG-3 within irdividuals, and urderstardirq of t h i s p t e n t i a l l y i q m r t a n t mmponent of the humvl 81 axis, the 1GF'P.P-3 level was determined in 309 serum samples obtained f m 23 boys over 4.1-6.4 yr; as they progressed ' 3 n q h plberty (assayed a t W o c r i n e scienoes) . IGFBP-3 c o x . ranged frcm 1.7 to 7.0 y / L .
EFFECT OF GROWH HORMONE (GH) ADMINISTRATION

GROWTH HORMONE RESPONSES TO GROWTH HORMONE RELEASING PEPTIDE (GRP) AND TO GROWTH HORMONE RELEASING HORMONE (GRF) IN GROWTH HORMONE DEFICIENT CHILDREN (GHD
'Though there was a general trerd of r i s i n g IGFW-3 c o x . wlth age (int+asubject ~0 . 3 3 , p<.001), values within injividuals often fluctuated unpredictably. However, intrasubject variability was signif. less than t h a t present i n t h e larger popllation . W e conclude t h a t the serum concentration of IGFBP.3 follows t h e general trend of an increase with age an3 pubertal stage s q g e s t e d by previous crms-sedional studies.
There is significant fluctuation over time within individuals suggestin3 rn caution when usirq t h i s a s a diagnostic tool though t h e r a q e of t h i s intra-irdividual S47 variation is t i g h t e r than that of the larger "no-1" m e .
